In today’s dynamic healthcare landscape, intensifying competition, evolving stakeholder dynamics, and the rise of digital and omnichannel strategies have heightened the complexity of resource planning for biopharma product launches. To remain competitive, drug manufacturers must align their investments in light of all these factors, leveraging data-driven insights to drive efficiency, maximize impact, and achieve long-term success.
This updated report from Best Practices, LLC benchmarks investment and resource allocation trends for pharmaceutical product launches across three pre-launch budget years through the launch year. Based on data from 61 pharmaceutical and biotech launches, the research delivers critical insights into resourcing for commercial, medical, and patient access value activities. It also examines evolving investment patterns pre- and post-COVID, offering detailed resourcing benchmarks by market archetype and Peak Year Sales Forecast (PYSF).
This updated version builds on previous research to equip brands with the latest benchmarks and actionable strategies to optimize launch budgets and resource planning, ensuring a competitive edge.